Format

Send to

Choose Destination
Cancer Discov. 2015 Jul;5(7):694-6. doi: 10.1158/2159-8290.CD-15-0616.

Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer.

Author information

1
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
2
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee. christine.lovly@vanderbilt.edu.

Abstract

In the setting of recent exciting clinical results and numerous ongoing trials, Piotrowska and colleagues explore mechanisms of acquired resistance to the mutant-specific EGFR inhibitor rociletinib, and demonstrate that loss of T790M, EGFR amplification, and small-cell transformation are all clinically relevant mechanisms of drug resistance. The authors provide a new paradigm for using quantitative assessment of the EGFR T790M:activation mutation allele frequency ratio to prognosticate responses to rociletinib and also demonstrate that plasma-based assessments of circulating tumor DNA can be used to monitor drug response and the emergence of drug resistance.

PMID:
26152920
PMCID:
PMC4499857
DOI:
10.1158/2159-8290.CD-15-0616
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center